Barclays PLC Harpoon Therapeutics, Inc. Transaction History

Barclays PLC

  • $327 Billion
  • Q2 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 03, 2023
BUY
$0.55 - $0.82 $14,865 - $22,163
27,029 Added 399.72%
33,791 $23,000
Q1 2023

May 04, 2023
BUY
$0.65 - $1.37 $390 - $822
600 Added 9.74%
6,762 $5,000
Q4 2022

Feb 13, 2023
SELL
$0.6 - $1.41 $4,958 - $11,652
-8,264 Reduced 57.29%
6,162 $4,000
Q2 2022

Aug 12, 2022
SELL
$1.78 - $5.02 $5,409 - $15,255
-3,039 Reduced 17.4%
14,426 $28,000
Q1 2022

May 16, 2022
SELL
$3.54 - $8.08 $69,617 - $158,901
-19,666 Reduced 52.96%
17,465 $88,000
Q4 2021

Feb 14, 2022
BUY
$5.69 - $7.83 $33,935 - $46,698
5,964 Added 19.14%
37,131 $281,000
Q3 2021

Nov 09, 2021
SELL
$7.88 - $14.0 $38,911 - $69,132
-4,938 Reduced 13.68%
31,167 $246,000
Q2 2021

Aug 13, 2021
BUY
$13.81 - $23.25 $262,624 - $442,145
19,017 Added 111.29%
36,105 $500,000
Q1 2021

May 13, 2021
BUY
$17.65 - $24.16 $6,565 - $8,987
372 Added 2.23%
17,088 $358,000
Q4 2020

Feb 11, 2021
BUY
$12.83 - $17.84 $24,287 - $33,771
1,893 Added 12.77%
16,716 $277,000
Q3 2020

Nov 12, 2020
SELL
$11.01 - $18.52 $91,140 - $153,308
-8,278 Reduced 35.83%
14,823 $252,000
Q2 2020

Aug 12, 2020
BUY
$11.11 - $24.72 $98,790 - $219,810
8,892 Added 62.58%
23,101 $383,000
Q1 2020

May 13, 2020
BUY
$10.74 - $16.32 $21,361 - $32,460
1,989 Added 16.28%
14,209 $164,000
Q4 2019

Feb 10, 2020
BUY
$12.94 - $20.58 $73,641 - $117,120
5,691 Added 87.16%
12,220 $180,000
Q3 2019

Nov 14, 2019
BUY
$10.93 - $17.47 $29,565 - $47,256
2,705 Added 70.74%
6,529 $89,000
Q2 2019

Aug 14, 2019
BUY
$10.0 - $13.03 $30,640 - $39,923
3,064 Added 403.16%
3,824 $50,000
Q1 2019

May 15, 2019
BUY
$9.47 - $17.01 $7,197 - $12,927
760 New
760 $7,000

Others Institutions Holding HARP

# of Institutions
2
Shares Held
353K
Call Options Held
0
Put Options Held
0
View Full List

About Harpoon Therapeutics, Inc.

HARP Quotes by TradingView
  • Ticker HARP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,106,800
  • Description
  • Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...
More about HARP
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email